MOTS-c and Sepsis-Induced Cardiomyopathy: A New Review Weighs the Mechanistic Case

Most of the MOTS-c literature covered on this blog sits in metabolic and exercise-physiology territory — AMPK signaling, glucose handling, mitochondrial biology broadly construed. A review published August 23 in the European Journal of Pharmacology moves into a different research area entirely: critical care medicine, and specifically sepsis-induced cardiomyopathy (SICM), a cardiac complication of sepsis marked by inflammatory dysregulation, mitochondrial dysfunction, and disrupted myocardial metabolism. The authors, a critical-care group at the Affiliated Hospital of Zunyi Medical University, set out to evaluate whether MOTS-c’s established biology gives it a plausible role in this specific condition.

What sepsis-induced cardiomyopathy involves

SICM is described in the review as a common cardiac complication of sepsis, distinguished from other forms of heart dysfunction by the combination of drivers involved: systemic inflammation, impaired mitochondrial function in cardiac tissue, metabolic disturbance, and changes to the myocardial microenvironment. Because mitochondrial dysfunction is central to SICM’s pathology, the authors reasoned that a mitochondrial-derived peptide with known metabolic and stress-responsive properties was worth examining as a research candidate — which is where MOTS-c enters the picture.

The mechanistic threads the review draws together

The review summarizes several lines of MOTS-c biology that are each independently established in other disease contexts and asks whether they translate to SICM specifically:

• AMPK-related energy metabolism — MOTS-c’s best-characterized effect, tying it to cellular energy regulation under metabolic stress.
• Antioxidant response — proposed effects on oxidative stress pathways relevant to mitochondrial dysfunction.
• Inflammatory restraint — effects on inflammatory signaling that would be directly relevant to sepsis’s systemic inflammatory component.
• Endothelial and microvascular protection — potentially relevant given the microvascular changes seen in septic cardiac tissue.
• Mitochondrial quality control — mechanisms governing how cells maintain functional mitochondria under stress.

Each of these is a real, previously published research thread. What the review adds is not new experimental data but a structured argument for why they might converge in SICM specifically.

Where the authors draw the line

The more notable part of this review is its explicit hedging. The authors state plainly that “direct SICM-specific evidence for MOTS-c” is limited, and that several of the mechanisms they discuss — stress-responsive nuclear signaling in particular — have been established primarily in non-SICM disease models rather than in sepsis or cardiac tissue itself. They frame MOTS-c as a “plausible but insufficiently validated molecule in SICM research,” and flag specific open questions that would need to be resolved before the idea goes further: biomarker specificity (does a MOTS-c signal actually track SICM rather than sepsis or critical illness generally), post-treatment efficacy, the identity of the target cells involved, and pharmacokinetic or biodistribution behavior under septic physiological conditions.

Why this matters for MOTS-c research more broadly

For a molecule with an increasingly wide research footprint — metabolic signaling, exercise physiology, thyroid autoimmunity, and now critical-care cardiology have all been explored in the peer-reviewed literature — this kind of scoping review is a useful marker of how far the science has and hasn’t gotten. It extends the map of research areas being explored for MOTS-c without claiming the underlying question is settled, which is a distinction worth keeping in mind when evaluating any narrative about a compound’s therapeutic potential: a mechanistically plausible hypothesis and a demonstrated effect in the specific disease context are not the same thing, and this review is explicit that SICM research on MOTS-c is currently the former.

Further reading

Zhao Z, Chen W, Zheng X, Geng Z, Dai N, Zhang H, Fu B, Fu X. “MOTS-c in sepsis-induced cardiomyopathy: Mechanisms and translational potential.” European Journal of Pharmacology, 2026 Aug 23;1033:179261. PubMed: 42633878 · doi.org/10.1016/j.ejphar.2026.179261